Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fraxiparine + Fraxodi
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
**Fraxiparine + Fraxodi** refers to the combination of standard Fraxiparine (nadroparin calcium 9,500 anti-Xa IU/mL) and Fraxodi (or Fraxiparine Forte, nadroparin calcium double strength 19,000 anti-Xa IU/mL), both low molecular weight heparin (LMWH) formulations used interchangeably for higher dosing needs in antithrombotic therapy. Nadroparin binds to antithrombin III (ATIII), accelerating inhibition of factor Xa and contributing to high antithrombotic potential, with additional mechanisms including stimulation of tissue factor pathway inhibitor (TFPI). Developed by Sanofi-Synthelabo (now Sanofi), it is primarily indicated for prevention of venous thromboembolism in surgical patients (general, orthopaedic), treatment of thromboembolic disorders, deep vein thrombosis, prevention of clotting during haemodialysis, and treatment of unstable angina/non-Q wave myocardial infarction (often with aspirin).
- Brand names
- Fraxiparine Forte
- Other names
- nadroparin calcium double strength solution for injection
02
Targets
F2 (Thrombin)F10 (Factor Xa)ATIII (Antithrombin III)TFPI (Tissue factor pathway inhibitor)
Beyond the preview
Go deeper on Fraxiparine + Fraxodi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fraxiparine + Fraxodi.